DecisionDx-GBM gene expression assay for prognostic testing in glioblastoma multiform

PLoS Currents

Volumn , Issue OCT, 2010, Pages

  Allingham Hawkins, Diane ^a   Lea, Andrew ^b   Levine, Susan ^c  

^a Hayes Inc   (Canada)

^b Hayes Inc   (New Zealand)

^c Health Technology Research and Consulting   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957889613     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1186     Document Type: Article

References (6)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
2. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer. 2010 Jun 1;9:135. Review. PubMed PMID: 20515495; PubMed Central PMCID: PMC2893101.
3. DecisionDx-GBM. Castle Biosciences. Accessed September 17, 2010
4. Decision-Dx-GBM. Castle Biosciences. Sample report Accessed October 5, 2010
5. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010 Jan;12(1):49-57. Epub 2009 Oct 20. PubMed PMID: 20150367.
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003. PubMed PMID: 15758010.